Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. Its lead product candidate is transcrocetinate sodium, which has initiated Phase 3 trials for the treatment of glioblastoma multiforme (GBM); Phase 2 clinical trials for the treatment of pancreatic cancer; Phase 2/3 clinical trials for the treatment of metastatic brain cancer; and Phase 2 trial for the treatment of stroke. The company is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of age-related macular degeneration; and is in pre-clinical development stage for the treatment of oncology primarily GBM. Diffusion Pharmaceuticals Inc. was founded in 2001 and is headquartered in Charlottesville, Virginia.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DFFN
CUSIPN/A
Phone434-220-0718
Debt
Debt-to-Equity RatioN/A
Current Ratio12.03
Quick Ratio12.04
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash Flow$0.1763 per share
Price / Cash2.59
Book Value$0.42 per share
Price / Book1.09
Profitability
EPS (Most Recent Fiscal Year)($1.14)
Net Income$-1,360,000.00
Net MarginsN/A
Return on Equity106.29%
Return on Assets51.04%
Miscellaneous
Employees11
Outstanding Shares50,530,000
Market Cap$23.07
Diffusion Pharmaceuticals (NASDAQ:DFFN) Frequently Asked Questions
What is Diffusion Pharmaceuticals' stock symbol?
Diffusion Pharmaceuticals trades on the NASDAQ under the ticker symbol "DFFN."
How were Diffusion Pharmaceuticals' earnings last quarter?
Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) issued its quarterly earnings results on Thursday, May, 10th. The company reported ($0.27) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.05) by $0.22. View Diffusion Pharmaceuticals' Earnings History.
When is Diffusion Pharmaceuticals' next earnings date?
What price target have analysts set for DFFN?
1 Wall Street analysts have issued 1-year price objectives for Diffusion Pharmaceuticals' stock. Their predictions range from $1.00 to $1.00. On average, they expect Diffusion Pharmaceuticals' share price to reach $1.00 in the next year. This suggests a possible upside of 119.0% from the stock's current price. View Analyst Ratings for Diffusion Pharmaceuticals.
What is the consensus analysts' recommendation for Diffusion Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diffusion Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Diffusion Pharmaceuticals' key competitors?
Some companies that are related to Diffusion Pharmaceuticals include SCYNEXIS (SCYX), Oncolytics Biotech (ONCY), Neurotrope (NTRP), Checkpoint Therapeutics (CKPT), Oramed Pharmaceuticals (ORMP), Sunesis Pharmaceuticals (SNSS), Elite Pharmaceuticals, Inc. Common Stock (ELTP), Medicure Inc. Common Stock (MCUJF), VIVUS (VVUS), Cardiome Pharma (CRME), Axsome Therapeutics (AXSM), GT Biopharma (GTBP), Vernalis (VNLPY), KemPharm (KMPH) and Novan (NOVN).
Who are Diffusion Pharmaceuticals' key executives?
Diffusion Pharmaceuticals' management team includes the folowing people:
- Mr. David G. Kalergis, Co-Founder, CEO & Chairman (Age 69)
- Dr. John L. Gainer, Co-Founder, Chief Scientific Officer & Director (Age 79)
- Mr. Ben L. Shealy, Sr. VP of Fin., Treasurer & Sec. (Age 59)
- Mr. Thomas E. Byrne, Gen. Counsel (Age 61)
- Dr. David Randolph Jones M.D., Chief Medical Officer (Age 55)
Has Diffusion Pharmaceuticals been receiving favorable news coverage?
News coverage about DFFN stock has trended somewhat positive on Monday, Accern reports. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Diffusion Pharmaceuticals earned a news impact score of 0.10 on Accern's scale. They also assigned news coverage about the company an impact score of 43.26 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.
How do I buy shares of Diffusion Pharmaceuticals?
Shares of DFFN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Diffusion Pharmaceuticals' stock price today?
One share of DFFN stock can currently be purchased for approximately $0.4566.
How big of a company is Diffusion Pharmaceuticals?
Diffusion Pharmaceuticals has a market capitalization of $23.07 million. The company earns $-1,360,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis. Diffusion Pharmaceuticals employs 11 workers across the globe.
How can I contact Diffusion Pharmaceuticals?
Diffusion Pharmaceuticals' mailing address is 1317 CARLTON AVENUE SUITE 200, CHARLOTTESVILLE VA, 22902. The company can be reached via phone at 434-220-0718 or via email at [email protected]
MarketBeat Community Rating for Diffusion Pharmaceuticals (NASDAQ DFFN)
MarketBeat's community ratings are surveys of what our community members think about Diffusion Pharmaceuticals and other stocks. Vote "Outperform" if you believe DFFN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DFFN will underperform the S&P 500 over the long term. You may vote once every thirty days.
